A House Energy and Commerce health subcommittee will discuss the Prescription Drug User Fee Act on Feb. 1 and proposed user fees for biosimilars Feb. 7. The subcommittee also scheduled a hearing Feb. 15 on reauthorization of the FDA's user-fee program for devices.

Full Story:
Hill, The

Related Summaries